Akshay Vaishnaw, MD, PhD

Dr. Akshay Vaishnaw has served as a member of our board of directors since May 2019. Dr. Vaishnaw joined Alnylam Pharmaceuticals in 2006, and currently serves as Chief Innovation Officer and is a member of its Scientific Advisory Board. Prior to Alnylam, he held various positions of increasing responsibility in clinical research and business development at Biogen, Inc., mostly recently Senior Director, Translational Medicine. Dr. Vaishnaw received a BS from University College Cardiff, U.K., an MD from the University of Wales College of Medicine, U.K., and a PhD in molecular immunology from the University of London, U.K. He is a Fellow of the Royal College of Physicians, U.K. Dr. Vaishnaw also serves on the Board of Directors for Editas Medicine Inc., Hemab Therapeutics, and as a Venture Partner at Atlas Venture.